9QE59QE5 の概要
| エントリーDOI | 10.2210/pdb9qe5/pdb |
| 関連するPDBエントリー | 9QE4 |
| 分子名称 | Elongin-B, Elongin-C, von Hippel-Lindau disease tumor suppressor, ... (5 entities in total) |
| 機能のキーワード | protac, degrader, complex, e3 ligase, vhl, vcb, ligase |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| タンパク質・核酸の鎖数 | 12 |
| 化学式量合計 | 198139.53 |
| 構造登録者 | |
| 主引用文献 | Wittenburg, S.,Zuleeg, M.R.,Peter, K.,Lemnitzer, P.,Voget, R.,Bricelj, A.,Gobec, M.,Dierlamm, N.,Braun, M.B.,Geiger, T.M.,Heim, C.,Stakemeier, A.,Wagner, K.G.,Nowak, R.P.,Hartmann, M.D.,Sosic, I.,Gutschow, M.,Kronke, J.,Steinebach, C. Enhancing Solubility in VHL-Based PROTACs: Optimized USP7 Degraders for Improved Developability. J.Med.Chem., 68:15711-15737, 2025 Cited by PubMed Abstract: Limited aqueous solubility, high total polar surface area (TPSA), and high hydrogen-bond donor (HBD) counts have hampered the clinical development of VHL-based proteolysis-targeting chimeras (PROTACs). This study explores strategies to enhance the physicochemical properties of VHL-recruiting USP7 degraders. By adjusting lipophilicity, HBD count, and TPSA, we created degraders with improved solubility while maintaining their USP7 degradation capability. Structural modifications at the VHL ligand included a constrained six-membered ring in the peptidic scaffold and the addition of solubilizing groups. These changes enhanced aqueous solubility without compromising degradation performance. A key example is PROTAC , modified with a dibasic piperazine, which exhibits a 170-fold increase in solubility over its predecessor while retaining strong target selectivity. The findings demonstrate that rational scaffold design can yield solubility-enhanced VHL-based PROTACs with broad potential for drug development. This methodology may also be applicable to other E3 ligases, supporting the development of degraders suitable for use. PubMed: 40673806DOI: 10.1021/acs.jmedchem.5c00718 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.5 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
をダウンロード
